CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Shifts in income, goals, or family needs make change necessary; use this guide to justify and implement thoughtful budget updates.
26,233 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
TTRF Capital Ltd quietly added a new stake in IREN Limited, buying 66,800 shares worth about $3.1 million. This shift...
If you’re planning for a decade of growth, two tech stocks stand out as durable picks. Here’s a clear, practical guid...
A down-market pullback can create a rare buying opportunity. This article explains how to spot a magnificent dividend...
When a market giant bets on housing, investors notice. This article dives into Berkshire Hathaway's $6.8 billion move...
A stock can jump this year, but chasing it blindly rarely ends well. This guide helps you assess whether the move jus...
Insider moves during earnings season can spark questions about a company’s future. This article dives into what it me...
A data center hardware maker saw a dramatic stock drop this week amid regulatory and supply chain concerns. This guid...
A director quietly sold a notable stake in American Superconductor, prompting questions about what it signals for inv...
An insider move at a biotech stage company can spark questions. This article breaks down the trade, its timing, and w...
A fintech just reported a blowout quarter, yet the stock still looks cheap to patient investors. This analysis breaks...
A single company dominates a crucial industry, changing the odds for investors. This piece breaks down what taiwan se...